Hephaistos-Pharma Raises $10.3M Seed Funding for Cancer Immunotherapy Development and Expansion

Hephaistos-Pharma's Seed Funding

Key Highlights:

• Seed Funding: Raised a total of $10.3 million in seed funding.
• Investors: Funding led by Elaia, with participation from xista sciences ventures, Fondation Fournier-Majoie, Noshaq, Angels Santé and Femmes Business Angels.
• Non-Dilutive Funding: Received €5.8 million in non-dilutive funding from the EIC accelerator, Bpifrance i-Nov, and France 2030 clinical grant.

Hephaistos-Pharma's Target Market

• Target Market: Focus on developing immunostimulants against cancer, particularly for metastatic and hard-to-treat indications.
• Biotechnology and Pharmaceutical Companies: Potential partners for collaboration in cancer immunotherapy research and development.
• Healthcare Providers and Institutions: Hospitals, clinics, and research institutions involved in cancer treatment and clinical trials.

What Hephaistos-Pharma Needs to Buy

• Research and Development Collaboration: Partnerships with academic institutions and research organizations for further development and clinical trials of their immunostimulant technology.
• Manufacturing and Supply Chain Solutions: Collaborating with manufacturers for the production of their immunostimulant products and managing a reliable supply chain.
• Regulatory and Compliance Services: Engaging with regulatory experts to navigate the complex landscape of cancer immunotherapy regulations and ensure compliance.